Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
- Conditions
- Bladder Pain SyndromeInterstitial Cystitis
- Interventions
- Drug: Onabotulinum Toxin A
- Registration Number
- NCT04401176
- Lead Sponsor
- Walter Reed National Military Medical Center
- Brief Summary
Recognition of interstitial cystitis (IC)/bladder pain syndrome (BPS) is increasing. There is a dire need to develop effective treatment options for these patients as it manifests as more than a physical disease, affecting general and psychological health as well. Existing trials comparing varying bladder instillation formulations have not identified an optimal bladder instillation therapy, however existing studies support combined heparin and alkalinized lidocaine bladder instillation as an affordable and effective treatment for IC/BPS. Additionally, intradetrusor onabotulinumtoxinA injection has been well established for the treatment of overactive bladder (OAB), a constellation of symptoms similar to that of IC/BPS. OnabotulinumtoxinA has now come into the forefront for treatment of OAB due to its efficacy, safety profile, and absence of cognitive effects related to the previous mainstay anticholinergic treatment. While both bladder instillation and onabotulinumtoxinA therapy have been shown to be effective for treatment of IC/BPS, a direct comparison of these treatments has not been performed. We therefore designed a randomized controlled trial to compare the efficacy of heparin with alkalized local anesthetic bladder instillation versus intradetrusor onabotulinumtoxinA injection in treating IC/BPS symptoms.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 58
- Females ≥ 18 years of age
- O'Leary-Sant questionnaire score ≥ 6
- Ability to follow study instructions and complete all required follow-up
- Contraindications and/or allergies to medications used
- Known alternative diagnosis explaining bladder pain symptoms
- Bladder instillation within the past 3 months
- Intradetrusor onabotulinumtoxinA injection within the past 6 months
- Use of ≥ 400 units of onabotulinumtoxinA in the last 3 months
- Inability or unwillingness to self-catheterize
- Post-void residual > 200mL
- Concurrent procedural treatment (including hydrodistension, sacral neuromodulation)
- Current use of vaginal pessary/devices
- Untreated symptomatic prolapse > pelvic organ prolapse quantification system (POP-Q) stage 2
- Females who are pregnant or planning a pregnancy during the study or who think that they may be pregnant at the start of the study and who are unwilling or unable to use a reliable form of contraception during the study
- Inability to speak/read English
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intradetrusor Onabotulinumtoxin A Injection Onabotulinum Toxin A 100 units onabotulinumtoxinA reconstituted in 10mL of injectable saline, injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone. Heparin & Alkalinized Lidocaine Bladder Instillation Heparin & Alkalinized Lidocaine Bladder Instillation Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
- Primary Outcome Measures
Name Time Method Change in O'Leary-Sant questionnaire scores from baseline between bladder instillation and intradetrusor onabotulinumtoxinA injection groups Baseline, 8-10 weeks Consists of O'Leary-Sant Symptom and Problem Index, total score 0-36.
- Secondary Outcome Measures
Name Time Method Change in Female Sexual Distress Scale-Revised (FSDS-R) score between bladder instillation and intradetrusor onabotulinumtoxinA injection groups Baseline, 4-6 weeks, 8-10 weeks FSDS-R evaluates distress associated with inadequate/impaired sexual function. Total score 0-52.
Change in bladder capacity between bladder instillation and intradetrusor onabotulinumtoxinA injection groups Baseline, 4-6 weeks, 8-10 weeks Bladder capacity via 1-day bladder diary
Incidence of adverse outcomes between bladder instillation and intradetrusor onabotulinumtoxinA injection groups 8-10 weeks Adverse outcomes to be defined specific to medication administered (urinary tract infection in both bladder instillation and onabotulinumtoxinA injection groups, urinary retention requiring catheterization, systemic effects related to onabotulinumtoxinA group only)
Patient perceptions of treatment between bladder instillation and intradetrusor onabotulinumtoxinA injection groups 6-9 months "How convenient or inconvenient was it to follow the treatment schedule as instructed?" (Scale 1-5 extremely inconvenient - extremely convenient) "How satisfied or dissatisfied are you in the ability of the treatment to treat your condition?" (Scale 1-5 extremely dissatisfied - extremely satisfied) "Taking all things into account, how satisfied or dissatisfied are you with this treatment?" (Scale 1-5 extremely dissatisfied - extremely satisfied) "How willing would you be to undergo this treatment again?" (Scale 1-5 extremely unwilling - extremely willing).
Change in pain scores using the Defense and Veterans Pain Rating Scale (visual analog scale) between bladder instillation and intradetrusor onabotulinumtoxinA injection groups Baseline, 4-6 weeks, 8-10 weeks, 6-9 months Scale of 0-10 (0= no pain, 10 = worst pain)
Change in Female Sexual Function Index (FSFI) score between bladder instillation and intradetrusor onabotulinumtoxinA injection groups Baseline, 4-6 weeks, 8-10 weeks FSFI evaluates 5 domains of female sexual function including desire, arousal, lubrication, orgasm, satisfaction, and pain. Total score 2-36.
Incidence of re-treatment between bladder instillation and intradetrusor onabotulinumtoxinA injection groups 6-9 months Re-treatment defined as additional course or crossover treatment outside of assigned treatment group
Change in O'Leary-Sant questionnaire scores from baseline between bladder instillation and intradetrusor onabotulinumtoxinA injection groups Baseline, 4-6 weeks, 6-9 months Consists of O'Leary-Sant Symptom and Problem Index. Total score 0-36
Change in 12-item Short Form Survey (SF-12) score between bladder instillation and intradetrusor onabotulinumtoxinA injection groups Baseline, 4-6 weeks, 8-10 weeks SF-12 is a general health questionnaire that evaluates quality of life measures, divided into mental and physical component scores.
Trial Locations
- Locations (1)
Walter Reed National Military Medical Center
🇺🇸Bethesda, Maryland, United States